These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 21166690)
1. Microglial alterations in human Alzheimer's disease following Aβ42 immunization. Zotova E; Holmes C; Johnston D; Neal JW; Nicoll JA; Boche D Neuropathol Appl Neurobiol; 2011 Aug; 37(5):513-24. PubMed ID: 21166690 [TBL] [Abstract][Full Text] [Related]
2. Neuroinflammation is associated with Alzheimer's disease co-pathology in dementia with Lewy bodies. Wetering JV; Geut H; Bol JJ; Galis Y; Timmermans E; Twisk JWR; Hepp DH; Morella ML; Pihlstrom L; Lemstra AW; Rozemuller AJM; Jonkman LE; van de Berg WDJ Acta Neuropathol Commun; 2024 May; 12(1):73. PubMed ID: 38715119 [TBL] [Abstract][Full Text] [Related]
3. Effect of active Aβ immunotherapy on neurons in human Alzheimer's disease. Paquet C; Amin J; Mouton-Liger F; Nasser M; Love S; Gray F; Pickering RM; Nicoll JA; Holmes C; Hugon J; Boche D J Pathol; 2015 Apr; 235(5):721-30. PubMed ID: 25430817 [TBL] [Abstract][Full Text] [Related]
4. Aβ43 in human Alzheimer's disease: effects of active Aβ42 immunization. Jäkel L; Boche D; Nicoll JAR; Verbeek MM Acta Neuropathol Commun; 2019 Sep; 7(1):141. PubMed ID: 31477180 [TBL] [Abstract][Full Text] [Related]
5. Microglial motility in Alzheimer's disease and after Aβ42 immunotherapy: a human post-mortem study. Franco-Bocanegra DK; George B; Lau LC; Holmes C; Nicoll JAR; Boche D Acta Neuropathol Commun; 2019 Nov; 7(1):174. PubMed ID: 31703599 [TBL] [Abstract][Full Text] [Related]
6. Aβ immunotherapy for Alzheimer's disease: effects on apoE and cerebral vasculopathy. Sakai K; Boche D; Carare R; Johnston D; Holmes C; Love S; Nicoll JA Acta Neuropathol; 2014 Dec; 128(6):777-89. PubMed ID: 25195061 [TBL] [Abstract][Full Text] [Related]
7. Inflammatory components in human Alzheimer's disease and after active amyloid-β42 immunization. Zotova E; Bharambe V; Cheaveau M; Morgan W; Holmes C; Harris S; Neal JW; Love S; Nicoll JA; Boche D Brain; 2013 Sep; 136(Pt 9):2677-96. PubMed ID: 23943781 [TBL] [Abstract][Full Text] [Related]
8. Phenotypic profile of alternative activation marker CD163 is different in Alzheimer's and Parkinson's disease. Pey P; Pearce RK; Kalaitzakis ME; Griffin WS; Gentleman SM Acta Neuropathol Commun; 2014 Feb; 2():21. PubMed ID: 24528486 [TBL] [Abstract][Full Text] [Related]
9. Downregulated apoptosis and autophagy after anti-Aβ immunotherapy in Alzheimer's disease. Paquet C; Nicoll JA; Love S; Mouton-Liger F; Holmes C; Hugon J; Boche D Brain Pathol; 2018 Sep; 28(5):603-610. PubMed ID: 29027727 [TBL] [Abstract][Full Text] [Related]
10. Microglial morphology in Alzheimer's disease and after Aβ immunotherapy. Franco-Bocanegra DK; Gourari Y; McAuley C; Chatelet DS; Johnston DA; Nicoll JAR; Boche D Sci Rep; 2021 Aug; 11(1):15955. PubMed ID: 34354209 [TBL] [Abstract][Full Text] [Related]
11. Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain. Boche D; Zotova E; Weller RO; Love S; Neal JW; Pickering RM; Wilkinson D; Holmes C; Nicoll JA Brain; 2008 Dec; 131(Pt 12):3299-310. PubMed ID: 18953056 [TBL] [Abstract][Full Text] [Related]
13. Fibrillar Aβ triggers microglial proteome alterations and dysfunction in Alzheimer mouse models. Sebastian Monasor L; Müller SA; Colombo AV; Tanrioever G; König J; Roth S; Liesz A; Berghofer A; Piechotta A; Prestel M; Saito T; Saido TC; Herms J; Willem M; Haass C; Lichtenthaler SF; Tahirovic S Elife; 2020 Jun; 9():. PubMed ID: 32510331 [TBL] [Abstract][Full Text] [Related]
14. Microglial immunophenotype in dementia with Alzheimer's pathology. Minett T; Classey J; Matthews FE; Fahrenhold M; Taga M; Brayne C; Ince PG; Nicoll JA; Boche D; J Neuroinflammation; 2016 Jun; 13(1):135. PubMed ID: 27256292 [TBL] [Abstract][Full Text] [Related]
15. Tau passive immunization inhibits not only tau but also Aβ pathology. Dai CL; Tung YC; Liu F; Gong CX; Iqbal K Alzheimers Res Ther; 2017 Jan; 9(1):1. PubMed ID: 28073379 [TBL] [Abstract][Full Text] [Related]
16. Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology. Serrano-Pozo A; William CM; Ferrer I; Uro-Coste E; Delisle MB; Maurage CA; Hock C; Nitsch RM; Masliah E; Growdon JH; Frosch MP; Hyman BT Brain; 2010 May; 133(Pt 5):1312-27. PubMed ID: 20360050 [TBL] [Abstract][Full Text] [Related]
17. Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer's disease pathogenesis. Boche D; Denham N; Holmes C; Nicoll JA Acta Neuropathol; 2010 Sep; 120(3):369-84. PubMed ID: 20632020 [TBL] [Abstract][Full Text] [Related]
18. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Holmes C; Boche D; Wilkinson D; Yadegarfar G; Hopkins V; Bayer A; Jones RW; Bullock R; Love S; Neal JW; Zotova E; Nicoll JA Lancet; 2008 Jul; 372(9634):216-23. PubMed ID: 18640458 [TBL] [Abstract][Full Text] [Related]
20. Active full-length DNA Aβ Rosenberg RN; Fu M; Lambracht-Washington D Alzheimers Res Ther; 2018 Nov; 10(1):115. PubMed ID: 30454039 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]